ALZHEIMER'SAN EFFORT MADE BY NANOSGROUP FOR ALZHEIMER'S

CUBX DRUG

Dr. Barnes, there is currently no cure for AD and no disease-modifying treatment, so the current best hope lies in identifying prevention strategies.

We believe our formulation will helpBy 2050, as many as 16 million Americans

will have Alzheimer's and the cost of care will surpass $1 trillion annually."

ALZHEIMER'S

The food and drug administration (FDA) has approved two drugs specifically to treat symptoms of alzheimer's disease.

Cholinesterase inhibitors

Memantine

Sold under the brand namenda by forest laboratories inc and germany's merz pharma, the drug had U.S.A Sales of about $1.2 billion last year.

For the study, researchers culled through published studies, presentations at medical meetings and other sources to find studies that looked at the effectiveness of the drug memantine, namenda's generic form, in patients with mild alzheimer's disease.

They found that memantine worked no better than a dummy pill at treating the disease.

ALZHEIMER'S

Under the microscope, there were widespread fatty deposits in small blood vessels, dead and dying brain cells, and abnormal protein amyloid deposits in and around cells.

AB1-40

Our Drug Formulation

Act on Extracellular neuritic amyloid plaques

Act on intracellular neurofibrillary tangles

Act as cholinesterase inhibitor

Growing concern

The value of the Alzheimer’s disease market across the seven major markets was $4.7bn in 2009 and is forecast to reach $11.9bn by 2019. Future market growth is set to be driven by the first disease-modifying drugs, given their significant price premium, likely therapeutic role as an adjunctive and potential utility in prodromal Alzheimer's diseaseDatamonitor forecasts that the current late-stage pipeline will yield three blockbusters, but this is by no means guaranteed considering the high risk of failure in Phase III Alzheimer’s disease trials. Of the pipeline drugs, Datamonitor believes that bapineuzumab and solanezumab have the most commercial and clinical potential.Datamonitor expects the symptomatic market will remain active in this disease. New symptomatic entrants to the market will include Aricept patch and the first-in-class 5-HT6 receptor antagonist SB-742457.

What can be done?

Worldwide, there are over 1000 published animal and human studies, both in vivo and in vitro in which the effects of curcumin on various diseases have

been examined. Studies include epidemiological, basic and clinical research on AD.

What can be done?

We took advantage of existing knowledge of curcumin and literature associated with its limitations.

The biggest limitation is its solubility and hence the absorption when consumed orally.

Stability is another issue CUBX has curcumin properties in it Our Hybrid Drug works Synergistically for

two pathological hallmark of AD i.e extracellular neuritic amyloid plaques and intracellular neurofibrillary tangles.

What we have done Hybrid DrugCUBXzil

We resolved the issue of solubility and stability of it

Our CUBXZIL molecule is soluble in water Our CUBXZIL is not altered by any

chemical Our CUBXZIL is stable

Progressive Stages of Alzheimer’s Disease

Stage 1. ( Early or Mild):

Short term memory problems May be unable to find the right words Forgets familiar names and telephone numbers Begins to write reminders but loses notes Shows preference for familiar things

(Wears the same clothes, Avoids going out) Judgment may be impaired

(May dress inappropriately for the weather)

We must try this drug to avoid progression

Progressive Stages of Alzheimer’s Disease

Stage 2a. (Middle or Moderate)):

Deterioration of ability to initiate and sequence purposeful activities like bathing and driving

Sleep disturbance with restlessness at night Begins to neglect health and hygiene Needs directions to function in familiar

surroundings

We must try this drug to avoid progression

Progressive Stages of Alzheimer’s Disease

Stage 2b. (Middle or Moderate) May lose ability to perform daily skills

(like buttoning a shirt or using a knife & fork) May need to be told each step of a former routine act

(like brushing teeth or getting dressed) May walk with a shuffling gait or may seem “glued to

the floor” due to a physical inability to walk Often needs physical assistance with activities of

daily living (dressing, bathing, eating) Needs protection and supervision May lose the ability to read or write

Progressive Stages of Alzheimer’s Disease

Stage 3. (Late or Final): Can’t walk May discontinue talking or be unable to

talk Trouble swallowing May have seizures Incontinence May make loud unintelligible negative noises or

sounds Complete withdrawal or apathy May lose control of outer extremities Unable to survive without total care

WE MUST ACT BEFORE THIS

Alzheimer’s is the fifth leading cause of disease death in the U.S.

Our molecule is really affordable to use. It is safe and is reported to help.

Become part of the solution and bringan end to this devastating disease!I will be really be glad even if I would able to contribute a little

Drug in use ? Generic Brand Approved For and Side Effects donepezil Aricept All stages Nausea, vomiting, loss of appetite and increased frequency of bowel movements. galantamine Razadyne Mild to moderate Nausea, vomiting, loss of appetite and increased frequency of bowel movements. memantine Namenda Moderate to severe Headache, constipation, confusion and dizziness. rivastigmine Exelon Mild to moderate Nausea, vomiting, loss of appetite and increased frequency of bowel movements. tacrine Cognex Mild to moderate Possible liver damage, nausea, and vomiting. vitamin E Not applicable Not approved Can interact with medications prescribed to lower cholesterol or prevent blood clots; may slightly increase risk of

death.

Science for CUBXZIL

At this point we can not disclose the full and final information about our nanomedicine compound drug.

Why to use our formulation CUBXZIL

Since ours is showing great results for arthritis and cancer.

Our is not formulated in any kind of protein Our is more stable and more potent

It is safe and we are looking for clinical collaboration.

Doctors, organizations or community help

FORMULATION

To treat inflammation To treat stress To treat cholinesterase inhibitor

Model of neural inflammation in AD.

CONTACT

Dr. Mewa Singhmewasinghsandhu@hotmail.com

www.nanomeda.comwww.nanosgroup.comLAETC, LSU Campus

Baton Rouge, LA